Efficacy of orbital radiotherapy in moderate-to-severe active graves’ orbitopathy including long-lasting disease: a retrospective analysis

Table 5 Comparison of outcome according to radiotherapy timing

	Early-active phase (n = 30)			Late-active phase (n = 32)
	Pre RT	6 months	p	Pre RT	6 months	p
CAS	3.07 ± 1.74	1.23 ± 1.28	< 0.001^a	3.00 ± 2.20	1.56 ± 1.58	< 0.001^a
Proptosis (mm)	18.20 ± 3.39	17.10 ± 3.32	0.002^a	19.00 ± 3.32	18.50 ± 2.83	0.061^a
MRD1 (mm)	3.99 ± 1.43	3.73 ± 1.45	0.905^a	4.15 ± 1.62	3.84 ± 1.30	0.199^a
PFH (mm)	9.41 ± 2.25	9.06 ± 1.89	0.658^a	9.80 ± 2.23	9.56 ± 2.10	0.407^b
Diplopia, Gorman score (number, %)			0.819^a			0.039^a
Absent	3 (10.0)	4 (13.2)		6 (18.8)	9 (28.1)
Intermittent	6 (20.0)	3 (10.0)		7 (21.9)	8 (25.0)
Inconstant	9 (30.0)	12 (40.0)		11 (34.4)	10 (31.2)
Constant	12 (40.0)	11 (36.7)		8 (25.0)	5 (15.6)
EOM movement≤30°, number of patients (%)	21 (70.0)	13 (43.3)	0.013^b	13 (40.6)	12 (37.5)	0.990^b
VA, logMAR	0.12 ± 0.17	0.02 ± 0.05	0.006^a	0.10 ± 0.23	0.04 ± 0.10	0.011^a
Number of CON (%)	7 (23.3)	1 (3.3)	0.077^b	6 (18.8)	2 (6.2)	0.134^b
IOP (mmHg)	19.00 ± 3.26	17.80 ± 3.59	0.018^b	16.80 ± 2.94	16.90 ± 3.71	0.468^a

CAS clinical activity score, MRD margin reflex distance, PFH palpebral fissure height, EOM extraocular muscle, VA visual acuity, IOP intraocular pressure ^a Wilcoxon signed rank test, ^b McNemar test

ISSN: 1748-717X